U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Fig. 1

Fig. 1. From: Release Characteristics of Quetiapine Fumarate Extended Release Tablets Under Biorelevant Stress Test Conditions.

Dissolution stress test device. a Schematic description of the apparatus, b photograph of one opened chamber with the paddle stirrer, c schematic representation of the agitation phases (site view), d arrangement of the test program

Grzegorz Garbacz, et al. AAPS PharmSciTech. 2014 Feb;15(1):230-236.
2.
Fig. 2

Fig. 2. From: Release Characteristics of Quetiapine Fumarate Extended Release Tablets Under Biorelevant Stress Test Conditions.

Dissolution profiles of quetiapine 50 mg ER tablets (a) and quetiapine 400 mg ER tablets (b) in the USP apparatus II at 100 rpm, 37°C, 1,000 mL fill volume, using HCL pH 1.0 and USP phosphate buffer pH 6.8 as dissolution media. Given are means of n = 6, the standard deviation is indicated by the error bars

Grzegorz Garbacz, et al. AAPS PharmSciTech. 2014 Feb;15(1):230-236.
3.
Fig. 3

Fig. 3. From: Release Characteristics of Quetiapine Fumarate Extended Release Tablets Under Biorelevant Stress Test Conditions.

Dissolution profiles of quetiapine 50 mg ER tablets (a) and quetiapine 400 mg ER tablets (b) in the dissolution stress test device under test program 2 and the USP apparatus II at 100 rpm, 37°C, 1,000 mL fill volume, using USP phosphate buffer pH 6.8 as dissolution media quetiapine 50 mg ER tablets (c) and quetiapine 400 mg ER tablets (d) tablets in the dissolution stress test device under test programs 1 and 2 and the USP apparatus II at 100 rpm, 37°C, 1,000 mL fill volume, using HCl pH 1.0 as dissolution media. Given are means of n = 6; the standard deviation is indicated by the error bars

Grzegorz Garbacz, et al. AAPS PharmSciTech. 2014 Feb;15(1):230-236.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center